Who are Sufentanil and dexmedetomidine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sufentanil-and-dexmedetomidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sufentanil and dexmedetomidine — Competitive Intelligence Brief

Sufentanil and dexmedetomidine (Sufentanil and dexmedetomidine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist and alpha-2 adrenergic agonist combination. Area: Anesthesia and Analgesia.

marketed Opioid agonist and alpha-2 adrenergic agonist combination Mu opioid receptor and alpha-2 adrenergic receptor Anesthesia and Analgesia Small molecule Live · refreshed every 30 min

Target snapshot

Sufentanil and dexmedetomidine (Sufentanil and dexmedetomidine) — Obstetrics & Gynecology Hospital of Fudan University. Sufentanil is an opioid agonist that binds mu receptors for analgesia and sedation, while dexmedetomidine is an alpha-2 adrenergic agonist that provides sedation and analgesia through central nervous system effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sufentanil and dexmedetomidine TARGET	Sufentanil and dexmedetomidine	Obstetrics & Gynecology Hospital of Fudan University	marketed	Opioid agonist and alpha-2 adrenergic agonist combination	Mu opioid receptor and alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist and alpha-2 adrenergic agonist combination class)

Obstetrics & Gynecology Hospital of Fudan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sufentanil and dexmedetomidine — Competitive Intelligence Brief. https://druglandscape.com/ci/sufentanil-and-dexmedetomidine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab